INTENSIFICATION DU TRAITEMENT CHELATEUR DU FER PAR LA DESFERRIOXAMINE A L'AIDE D'UNE CHAMBRE IMPLANTABLE D'ACCESS VEINEUX (PORT-A-CATH)

Translated title of the contribution: Intensifying iron chelating therapy with deferoxamine using implanted venous access catheters (Port-A-Cath)

M. De Montalembert, Dominique M. Jan, M. Clairicia, T. Hannedouche, D. Sidi, R. Girot

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Deferoxamine is still today the only preventive and curative treatment of transfusional hemochromatosis. It must be perfused daily, intravenously or subcutaneously, during several hours emplantable infusion devices (Port-A-Cath) offer intravenous access, allowing to use higher doses, while avoiding local swelling due to subcutaneous injections. This device was inserted in 7 major thalassemic patients who presented with severe complications of iron overload, including 4 of them with signs of cardiac failure. Ferritinemias of all patients were lowered after intensifying iron chelation: cardiac function improved drastically in 2 patients. Devices were responsible for some complications: occlusion in one patient, local infections in two. This way of administration of desferal seems useful in patients with high ferritinemia and/or organic complications related to hemochromatosis.

Original languageFrench
Pages (from-to)159-163
Number of pages5
JournalArchives Francaises de Pediatrie
Volume49
Issue number3
StatePublished - 1992
Externally publishedYes

Fingerprint

Vascular Access Devices
Deferoxamine
Catheters
Iron
Hemochromatosis
Equipment and Supplies
Therapeutics
Iron Overload
Subcutaneous Injections
Heart Failure
Infection

Keywords

  • blood transfusion
  • child
  • deferoxamine
  • heart failure congestive
  • hemosiderosis
  • Thalassemia

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

INTENSIFICATION DU TRAITEMENT CHELATEUR DU FER PAR LA DESFERRIOXAMINE A L'AIDE D'UNE CHAMBRE IMPLANTABLE D'ACCESS VEINEUX (PORT-A-CATH). / De Montalembert, M.; Jan, Dominique M.; Clairicia, M.; Hannedouche, T.; Sidi, D.; Girot, R.

In: Archives Francaises de Pediatrie, Vol. 49, No. 3, 1992, p. 159-163.

Research output: Contribution to journalArticle

@article{c047eabddb214e69bd0ac88157f2c075,
title = "INTENSIFICATION DU TRAITEMENT CHELATEUR DU FER PAR LA DESFERRIOXAMINE A L'AIDE D'UNE CHAMBRE IMPLANTABLE D'ACCESS VEINEUX (PORT-A-CATH)",
abstract = "Deferoxamine is still today the only preventive and curative treatment of transfusional hemochromatosis. It must be perfused daily, intravenously or subcutaneously, during several hours emplantable infusion devices (Port-A-Cath) offer intravenous access, allowing to use higher doses, while avoiding local swelling due to subcutaneous injections. This device was inserted in 7 major thalassemic patients who presented with severe complications of iron overload, including 4 of them with signs of cardiac failure. Ferritinemias of all patients were lowered after intensifying iron chelation: cardiac function improved drastically in 2 patients. Devices were responsible for some complications: occlusion in one patient, local infections in two. This way of administration of desferal seems useful in patients with high ferritinemia and/or organic complications related to hemochromatosis.",
keywords = "blood transfusion, child, deferoxamine, heart failure congestive, hemosiderosis, Thalassemia",
author = "{De Montalembert}, M. and Jan, {Dominique M.} and M. Clairicia and T. Hannedouche and D. Sidi and R. Girot",
year = "1992",
language = "French",
volume = "49",
pages = "159--163",
journal = "Archives de Pediatrie",
issn = "0929-693X",
publisher = "Elsevier Masson",
number = "3",

}

TY - JOUR

T1 - INTENSIFICATION DU TRAITEMENT CHELATEUR DU FER PAR LA DESFERRIOXAMINE A L'AIDE D'UNE CHAMBRE IMPLANTABLE D'ACCESS VEINEUX (PORT-A-CATH)

AU - De Montalembert, M.

AU - Jan, Dominique M.

AU - Clairicia, M.

AU - Hannedouche, T.

AU - Sidi, D.

AU - Girot, R.

PY - 1992

Y1 - 1992

N2 - Deferoxamine is still today the only preventive and curative treatment of transfusional hemochromatosis. It must be perfused daily, intravenously or subcutaneously, during several hours emplantable infusion devices (Port-A-Cath) offer intravenous access, allowing to use higher doses, while avoiding local swelling due to subcutaneous injections. This device was inserted in 7 major thalassemic patients who presented with severe complications of iron overload, including 4 of them with signs of cardiac failure. Ferritinemias of all patients were lowered after intensifying iron chelation: cardiac function improved drastically in 2 patients. Devices were responsible for some complications: occlusion in one patient, local infections in two. This way of administration of desferal seems useful in patients with high ferritinemia and/or organic complications related to hemochromatosis.

AB - Deferoxamine is still today the only preventive and curative treatment of transfusional hemochromatosis. It must be perfused daily, intravenously or subcutaneously, during several hours emplantable infusion devices (Port-A-Cath) offer intravenous access, allowing to use higher doses, while avoiding local swelling due to subcutaneous injections. This device was inserted in 7 major thalassemic patients who presented with severe complications of iron overload, including 4 of them with signs of cardiac failure. Ferritinemias of all patients were lowered after intensifying iron chelation: cardiac function improved drastically in 2 patients. Devices were responsible for some complications: occlusion in one patient, local infections in two. This way of administration of desferal seems useful in patients with high ferritinemia and/or organic complications related to hemochromatosis.

KW - blood transfusion

KW - child

KW - deferoxamine

KW - heart failure congestive

KW - hemosiderosis

KW - Thalassemia

UR - http://www.scopus.com/inward/record.url?scp=0026822999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026822999&partnerID=8YFLogxK

M3 - Article

C2 - 1610270

AN - SCOPUS:0026822999

VL - 49

SP - 159

EP - 163

JO - Archives de Pediatrie

JF - Archives de Pediatrie

SN - 0929-693X

IS - 3

ER -